Cyclacel Pharmaceuticals Q1 2025: Deconsolidation Gain, FITTERS Exchange, Focus on Plogosertib

Bio Green Med Solution, Inc.

2025-Q1 EPS reported $0.00

Cyclacel reported Q1 2025 net loss of $0.1 million, compared to $2.9 million in Q1 2024.
Deconsolidation of UK subsidiary Cyclacel Limited resulted in a $5.0 million gain on deconsolidation.
Company repurchased plogosertib assets from Cyclacel Limited for approximately $0.3 million.
Entered into an Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd. for 19.99% of common stock.
Cash and cash equivalents totaled $3.5 million as of March 31, 2025, expected to fund into Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.